Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study

Arcellx Incorporated (NASDAQ:ACLX) is one of 17 biotechnology stocks with more than 50% upside. On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral. In the process, he also reduced the price target from $113 to $82, which still yields a revised upside potential of almost 20%. Ding’s views are based on his conservative stance on the company’s CAR-T cell therapy class amid rising competition across larger markets in other mod ...